Attenuated levels of pro-inflammatory markers in diabetic retinopathy patients undergoing treatment with antihyperglycemic and antihypertensive drugs

Clinics

Volumn 68, Issue 2, 2013, Pages 185-191

  Ng, Zhi Xiang ^a   Chua, Kek Heng ^a   Tajunisah, Iqbal ^a   Pendek, Rokiah ^a   Kuppusamy, Umah Rani ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Antihyperglycemic; Antihypertensive; Diabetic retinopathy; Monocyte chemotactic protein 1; Nuclear factor kappa B

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR RELA;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CASE CONTROL STUDY; DIABETIC RETINOPATHY; FEMALE; HUMAN; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CCL2; DIABETIC RETINOPATHY; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TRANSCRIPTION FACTOR RELA;

EID: 84875643903     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(02)OA11     Document Type: Article

References (27)

1. Uthra S, Raman R, Mukesh BN, Rajkumar SA, Padmaja KR, Paul PG, et al. Association of vegf gene polymorphisms with diabetic retinopathy in a south indian cohort. Ophthalmic Genet. 2008;29(1):11-5, http://dx. doi.org/10.1080/13816810701663527.
2. Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin. 2009;49(2):35-52, http://dx. doi.org/10.1097/IIO.0b013e31819fd5d7.
3. Lamoureux EL, Tai ES, Thumboo J, Kawasaki R, Saw SM, Mitchell P, et al. Impact of diabetic retinopathy on vision-specific function. Ophthalmology. 2010;117(4):757-65, http://dx.doi.org/10.1016/j.ophtha. 2009.09.035.
4. Cai J, Boulton M. The pathogenesis of diabetic retinopathy: Old concepts and new questions. Eye (Lond). 2002;16(3):242-60, http://dx.doi.org/10. 1038/sj.eye.6700133.
5. Ozturk BT, Bozkurt B, Kerimoglu H, Okka M, Kamis U, Gunduz K. Effect of serum cytokines and vegf levels on diabetic retinopathy and macular thickness. Mol Vis. 2009;15(12):1906-14.
6. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-36, http://dx.doi.org/10.1016/S0140-6736(09)62124-3.
7. Ho E, Bray TM. Antioxidants, nfkappab activation, and diabetogenesis. Proc Soc Exp Biol Med. 1999;222(3):205-13, http://dx.doi.org/10.1046/j. 1525-1373.1999.d01-137.x.
8. Christiansen T, Richelsen B, Bruun JM. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond). 2005;29(1):146-50, http://dx.doi.org/10.1038/sj.ijo.0802839.
9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (ukpds 34). Uk prospective diabetes study (ukpds) group. Lancet. 1998;352(9131):854-65.
10. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: Ukpds 39. Uk prospective diabetes study group. BMJ. 1998;317(7160):713-20.
11. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (direct-prevent 1) and progression (direct-protect 1) of retinopathy in type 1 diabetes: Randomised, placebocontrolled trials. Lancet. 2008;372(9647):1394-1402, http://dx.doi.org/10. 1016/S0140-6736(08)61412-9.
12. Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (direct-protect 2): A randomised placebo-controlled trial. Lancet. 2008;372(9647):1385-93, http://dx.doi.org/10.1016/S0140-6736 (08)61411-7.
13. Diabetic retinopathy study. Report number 6. Design, methods, and baseline results. Report number 7. A modification of the airlie house classification of diabetic retinopathy. Prepared by the diabetic retinopathy. Invest Ophthalmol Vis Sci. 1981;21(1 Pt 2):1-226.
14. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified airlie house classification. Etdrs report number 10. Early treatment diabetic retinopathy study research group. Ophthalmology. 1991;98(5 Suppl):786-806.
15. Boyum A. Separation of leukocytes from blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl. 1968;97:7.
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54, http://dx.doi.org/10.1016/0003-2697(76)90527-3.
17. Meleth AD, Agron E, Chan CC, Reed GF, Arora K, Byrnes G, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46(11):4295-301, http://dx.doi.org/10.1167/iovs.04-1057.
18. Harada C, Okumura A, Namekata K, Nakamura K, Mitamura Y, Ohguro H, et al. Role of monocyte chemotactic protein-1 and nuclear factor kappa b in the pathogenesis of proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2006;74(3):249-56, http://dx.doi.org/10.1016/j. diabres.2006.04.017.
19. Hashimoto S, Nakayama T, Gon Y, Hata N, Koura T, Maruoka S, et al. Correlation of plasma monocyte chemoattractant protein-1 (mcp-1) and monocyte inflammatory protein-1alpha (mip-1alpha) levels with disease activity and clinical course of sarcoidosis. Clin Exp Immunol. 1998;111(3):604-10, http://dx.doi.org/10.1046/j.1365-2249.1998.00519. x.
20. Hofmann MA, Schiekofer S, Isermann B, Kanitz M, Henkels M, Joswig M, et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor nf-kappab. Diabetologia. 1999;42(2):222-32, http://dx.doi.org/10.1007/s001250051142.
21. Wakabayashi Y, Usui Y, Okunuki Y, Kezuka T, Takeuchi M, Iwasaki T, et al. Increases of vitreous monocyte chemotactic protein 1 and interleukin 8 levels in patients with concurrent hypertension and diabetic retinopathy. Retina. 2011;31(9):1951-57, http://dx.doi.org/10. 1097/IAE.0b013e31820d3cee.
22. Nagai N, Izumi-Nagai K, Oike Y, Koto T, Satofuka S, Ozawa Y, et al. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin ii type 1 receptor or its downstream nuclear factor-kappab pathway. Invest Ophthalmol Vis Sci. 2007;48:4342-50, http://dx.doi.org/10.1167/iovs.06-1473.
23. Sarlos S, Wilkinson-Berka JL. The renin-angiotensin system and the developing retinal vasculature. Invest Ophthalmol Vis Sci. 2005;46(9):1069-77, http://dx.doi.org/10.1167/iovs.04-0885.
24. Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res. 2010;29(4):284-311, http://dx.doi.org/10.1016/j.preteyeres.2010.03.003.
25. Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S. Agents that block advanced glycation end product (age)-rage (receptor for ages)-oxidative stress system: A novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs. 2008;17(7):983-96, http://dx.doi.org/10.1517/13543784.17.7.983.
26. Ng ZX, Kuppusamy UR, Tajunisah I, Fong KC, Koay AC, Chua KH. 2245g/a polymorphism of the receptor for advanced glycation endproducts (rage) gene is associated with diabetic retinopathy in the malaysian population. Br J Ophthalmol. 2012;96(2):289-92, http://dx.doi. org/10.1136/bjophthalmol-2011-300658.
27. Treins C, Giorgetti-Peraldi S, Murdaca J, Monthouel-Kartmann MN, Van Obberghen E. Regulation of hypoxia-inducible factor (hif)-1 activity and expression of hif hydroxylases in response to insulin-like growth factor. Mol Endocrinol. 2005;19(5):1304-17, http://dx.doi.org/10.1210/me.2004-0239.